Physician profile
Jing Yu
NPI 1598711285
$2,624.23
in general payments reported to CMS, 2019-2025
21 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $136 · 2021: $264 · 2022: $393 · 2023: $376 · 2024: $477 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.65 |
| Education | $171.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $683.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $387.95 | 2019-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $356.22 | 2022-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $284.85 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $185.51 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $145.90 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $127.58 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $82.43 | 2022-2024 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $76.97 | 2020-2022 | |
| Allergan, INC. | $51.27 | 2021 | |
| Ucb, INC. | $47.97 | 2024-2025 | Nayzilam |
| Boston Scientific Corporation | $35.05 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.72 | 2020 | |
| Amgen INC. | $22.63 | 2024 | Otezla, Repatha |
| Dexcom, INC. | $21.11 | 2025 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.74 | 2019 | |
| Lucid Diagnostics INC. | $16.75 | 2024 | |
| Jazz Pharmaceuticals INC. | $16.47 | 2024 | |
| Echosens North America, INC. | $14.61 | 2025 | Fibroscan |
| Astrazeneca Pharmaceuticals LP | $14.10 | 2020 | |
| Seqirus USA INC | $11.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jing Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.